Systebryl

Systebryl (PTI-110) is a small molecule drug developed by ProteoTech (and later ProtaMed) for the treatment of AL amyloidosis, a rare systemic disease characterized by the accumulation of misfolded protein aggregates. The drug specifically targets and disaggregates insoluble immunoglobulin light chain (AL) amyloid deposits that build up in vital organs such as the heart and kidneys. By breaking down these deposits, Systebryl is intended to facilitate their clearance from the body and restore organ function. Although it received FDA orphan drug designation in January 2015 and was planned for Phase 1/2 clinical trials, development appears to have stalled, and the trademark was abandoned in 2016.

Brand names

Systebryl

Other names

N-(3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide